RA
NAGE

Royce & Associates’s Niagen Bioscience NAGE Stock Holding History

Royce & Associates’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.8K Buy
+12,169
New +$49.4K ﹤0.01% 747

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Royce & Associates's NAGE Position: Q2 2026 in Review

Royce & Associates opened a new position in Niagen Bioscience (NAGE) in Q2 2026: 12,169 shares worth $38.8K. The stake represents ﹤0.01% of the portfolio and ranks #747 among its holdings.

140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Royce & Associates held 12,169 shares of Niagen Bioscience worth $38.8K as of Q2 2026.
  • Niagen Bioscience was a new Royce & Associates position in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of Royce & Associates's portfolio in Q2 2026, its #747 holding.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.